With over $2.9B assets under management, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies, focusing on Life Sciences and Growth Buyout investments.

Life Sciences

Acquired by AstraZeneca in 2016
IPO in 2015 (NASDAQ: COLL)
Acquired by Valeant Pharmaceuticals in 2014
Acquired by The Medicines Company in 2013

Growth Buyout

Acquired by The Partners Group


Frazier Healthcare Partners

James Topper Included in 2016 Midas List

Frazier Healthcare Partners

Frazier Healthcare Partners Closes on New $525 Million Growth Buyout Fund


Partners Group to acquire PCI Pharma Services, a leading global provider of outsourced pharmaceutical services

Silvergate Pharmaceuticals

FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older